Ignite Creation Date:
2024-05-06 @ 2:31 PM
Last Modification Date:
2024-10-26 @ 1:32 PM
Study NCT ID:
NCT04343859
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2023-11-09
First Post:
2020-03-23
Brief Title:
A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors
Sponsor:
Tianjin Chasesun Pharmaceutical Co LTD
Organization:
Tianjin Chasesun Pharmaceutical Co LTD
Study Overview
Official Title:
A Phase I Clinical Trial of IMMH-010 in Patients With Advanced Malignant Solid Tumors
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2022-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase I study of IMMH-010 in patients with advanced malignant solid tumors
Detailed Description:
To evaluate the safety and tolerability of single-dose and multi-dose IMMH-010 in patients with advanced solid tumors et al
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None